Shanghai Pharmaceuticals Holding Co., Ltd
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS9
PHASE 3 / 2-32
RECRUITING8
READOUTS ≤12 MONTHS6
READOUT SLIPPED >6 MO88%
Delay Index: of 8 active trials registered more than a year ago, 7 have moved their primary completion (readout) date by more than 6 months since first registration (median +20.0 months). See all sponsors →
Open Shanghai Pharmaceuticals Holding Co., Ltd on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| SPH4336 Tablets 400mg NCT05744687 |
P2/3 | Recruiting | Locally Advanced or Metastatic Breast Cancer | 374 | 2026-05-31 (+21 mo) |
| T3011 NCT06214156 |
P1/2 | Recruiting | Advanced Melanoma | 42 | 2026-09-30 (+24 mo) |
| SPH4336 Tablets NCT05860465 |
P2/3 | Recruiting | Locally Advanced or Metastatic Breast Cancer | 254 | 2026-12-01 (+21 mo) |
| LT3001 Drug:high dose NCT05686642 |
P2 | Recruiting | Acute Ischemic Stroke | 300 | 2026-12-10 (+20 mo) |
| T3011 high dose NCT06214143 |
P1/2 | Recruiting | Advanced Solid Tumors | 68 | 2026-12-31 (+12 mo) |
| SPH4336 Tablets NCT05872347 |
P2 | Recruiting | Breast Cancer Brain Metastases | 52 | 2026-12-31 (+12 mo) |
| SPH4336 NCT05944224 |
P1/2 | Recruiting | Advanced Solid Tumors | 63 | 2026-12-31 (+19 mo) |
| SPH5030 NCT06434597 |
P2 | Recruiting | Biliary Tract or Colorectal Cancer With Her2-positive/Mutated | 60 | 2026-12-31 |
| LT3001 Drug:high dose NCT07754825 |
P2 | Not yet recruiting | Acute Ischemic Stroke | 300 | 2027-12-31 |